In prostate carcinoma (PCC) cells DU-145 and LNCaP, cannabichromene was found to be the second most potent inhibitor of cell viability behind CBD, and CBC at 10 μM had very little effect on caspase 3/7 activity. Here, CASP3 is linked to prostate carcinoma.